Capricor Therapeutics
An Analytical Development Scientist at Capricor Therapeutics develops, optimizes, and validates complex analytical methods for cell therapy and biologic products. This role leads cross-functional projects, drives assay strategy, and ensures alignment with regulatory expectations and program timelines.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2005
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a San Diego–based biotechnology company developing cell- and exosome-based therapeutics for muscular and other select diseases. Its lead candidate, deramiocel (CAP‑1002), is an allogeneic cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. Capricor is also advancing exosome technology as a next‑generation platform, engineering exosomes to deliver nucleic acids and proteins to treat or prevent a variety of diseases. The company focuses on translating these platforms into novel therapeutic and preventive products.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Capricor Therapeutics.
Right around the average for this role
Duchenne trial drug from Capricor slows key task decline 83%
23 hours ago
Senior Scientist I, Analytical Development, Biologics CMC
Exelixis
Scientist, Analytical Cell Line Engineering & Bioassay Development
BioLife Plasma Services
Cell Potency Analytical Development Lead
Artiva Biotherapeutics
Senior/Principal Scientist, Analytical Cell Line Engineering and Bioassay Development
Takeda Pharmaceutical Company Limited
Analytical Development Scientist
Artiva Biotherapeutics
Scientist, Cell Therapy
BeOne Medicines